Search

Your search keyword '"den Dekker, W K"' showing total 10 results
Start Over Author "den Dekker, W K"
10 results on '"den Dekker, W K"'

4. Predictors of successful post-PCI optimization in vessels with post-PCI fractional flow reserve <0.90: findings from the FFR REACT trial

Author

Neleman, T, primary, Ziedses Des Plantes, A C, additional, Scoccia, A, additional, Groenland, F T W, additional, Van Zandvoort, L J C, additional, Ligthart, J M R, additional, Witberg, K T, additional, Boersma, H, additional, Nuis, R J, additional, Den Dekker, W K, additional, Diletti, R, additional, Wilschut, J, additional, Van Mieghem, N M, additional, and Daemen, J, additional

Published
2023
Full Text
View/download PDF

6. Immediate versus staged revascularisation of non-culprit arteries in patients with acute coronary syndrome:a systematic review and meta-analysis

Author

Vriesendorp, P A, Wilschut, J M, Diletti, R, Daemen, J, Kardys, I, Zijlstra, F, Van Mieghem, N M, Bennett, J, Esposito, G, Sabate, M, den Dekker, W K, Vriesendorp, P A, Wilschut, J M, Diletti, R, Daemen, J, Kardys, I, Zijlstra, F, Van Mieghem, N M, Bennett, J, Esposito, G, Sabate, M, and den Dekker, W K

Abstract

Although there is robust evidence that revascularisation of non-culprit vessels should be pursued in patients presenting with an acute coronary syndrome (ACS) and multivessel coronary artery disease (MVD), the optimal timing of complete revascularisation remains disputed. In this systematic review and meta-analysis our results suggest that outcomes are comparable for immediate and staged complete revascularisation in patients with ACS and MVD. However, evidence from randomised controlled trials remains scarce and cautious interpretation of these results is recommended. More non-biased evidence is necessary to aid future decision making on the optimal timing of complete revascularisation.

Published
2022

9. Safety of endomyocardial biopsy in new-onset acute heart failure requiring veno-arterial extracorporeal membrane oxygenation

Author

Van Der Boon, R M A, primary, Den Dekker, W K, additional, Meuwese, C L, additional, Lorusso, R, additional, Von Der Thusen, J H, additional, Constantinescu, A C, additional, Manintveld, O C, additional, Delnoij, T S R, additional, Van Der Heijden, J J, additional, Van Mieghem, N M D A, additional, and Den Uil, C A, additional

Published
2021
Full Text
View/download PDF

10. Percutaneous complete revascularization strategies using sirolimus-eluting biodegradable polymer-coated stents in patients presenting with acute coronary syndrome and multivessel disease: Rationale and design of the BIOVASC trial

Author

Giovanni Esposito, Paul Cummins, Rutger J. van Bommel, Eric Boersma, Matthias Vrolix, BioVasc Trial Investigators, Johan Bennett, Mattie J. Lenzen, Manel Sabaté, Joost Daemen, Roberto Diletti, Nicolas M. Van Mieghem, Felix Zijlstra, Wijnand K den Dekker, Cardiology, den Dekker, W. K., Van Mieghem, N. M., Bennett, J., Sabate, M., Esposito, G., van Bommel, R. J., Daemen, J., Vrolix, M., Cummins, P. A., Lenzen, M. J., Boersma, E., Zijlstra, F., and Diletti, R.

Subjects
medicine.medical_specialty, Acute coronary syndrome, Percutaneous, Polymers, medicine.medical_treatment, Equivalence Trials as Topic, 030204 cardiovascular system & hematology, Revascularization, Prosthesis Design, BioVasc Trial Investigators, 03 medical and health sciences, 0302 clinical medicine, Percutaneous Coronary Intervention, Absorbable Implant, Absorbable Implants, medicine, Clinical endpoint, Drug-Eluting Stent, Humans, Multicenter Studies as Topic, Sirolimu, 030212 general & internal medicine, Myocardial infarction, Prospective Studies, Acute Coronary Syndrome, Prospective cohort study, Polymer, Randomized Controlled Trials as Topic, Sirolimus, business.industry, Percutaneous coronary intervention, Drug-Eluting Stents, medicine.disease, Surgery, Prospective Studie, Cardiology and Cardiovascular Medicine, business, medicine.drug, Human
Abstract

BACKGROUND: Complete revascularization in patients with an acute coronary syndrome and multivessel disease is superior compared to culprit-only treatment. However, it is unknown whether direct complete or staged complete revascularization should be pursued. METHODS: The BIOVASC study is an investigator-initiated, prospective, multicenter, randomized, 2-arm, international, open-label, noninferiority trial. We will randomize 1,525 patients 1:1 to immediate complete revascularization (experimental arm) or culprit-only plus staged complete revascularization (control arm). Patients will be enrolled in approximately 30 sites in Belgium, Italy, the Netherlands, and Spain. The primary end point is a composite of all-cause mortality, nonfatal myocardial infarction, any unplanned ischemia-driven revascularization (excluding staged procedures in the control arm at the predetermined time), and cerebrovascular events (MACCE) at 1 year post index procedure. CONCLUSIONS: The BIOVASC study aims to further refine the treatment algorithm for acute coronary syndrome patients with multivessel disease in terms of optimal timing for complete revascularization (Clinicaltrials.gov NCT03621501). ispartof: AMERICAN HEART JOURNAL vol:227 pages:111-117 ispartof: location:United States status: published

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results